The regenerative medicine and immunotherapy laboratories are focused on developing new cellular therapies for end-stage organ diseases and post-transplant complications, and validating new vaccination strategies for infectious diseases.

The activities are shared with the IRCCS ISMETT team.

The team includes researchers and technical staff specialized in research and development (in vitro, in vivo and first-in-man studies) and manipulation of biological samples of human origin. The team was trained to operate according to Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) for designing and performing preclinical/clinical trials and producing advanced therapies.

The projects undergoing preclinical phase aim at developing cellular products for tissue repair and/or regeneration and developing organotypic cultures to be used for regenerative purposes and as models for pharmacological screening.

Another important research focus is the study and development of cellular therapies for the prevention of disease recurrences and the treatment of post-transplant infections. Some projects are developed in close collaboration with the UP and UPMC teams in Pittsburgh.

This allows to accelerate preclinical development process towards the patient, thanks to the transfer of protocols and know-how. The new generation of vaccines, made up of re-combined proteins, aims at treating hospital-acquired infections of different etiology.